Final answer:
Baseline testing before initiation of novel oral anticoagulation therapy (NOAC) for chronic atrial fibrillation is important to assess the patient's baseline characteristics, identify potential risk factors, and determine the appropriate dosage of the NOAC.
Step-by-step explanation:
Baseline testing before initiation of novel oral anticoagulation therapy (NOAC) for chronic atrial fibrillation is important to assess the patient's baseline characteristics, identify potential risk factors, and determine the appropriate dosage of the NOAC.
Baseline testing may involve various laboratory tests such as complete blood count, liver function tests, and renal function tests. These tests help evaluate the patient's overall health and determine if there are any specific contraindications or precautions that need to be taken into consideration before starting the NOAC.
Additionally, baseline testing may include an electrocardiogram (ECG) to assess the heart's electrical activity and identify any underlying abnormalities that may require further evaluation or management.